Canaccord Genuity Starts Amgen Coverage at Hold with $366 Target as Growth Offsets Legacy Declines
Canaccord Genuity initiated coverage of Amgen (AMGN) with a Hold rating and $366 price target on [recent date, per signal]. The call reflects Amgen's resilient revenue trajectory—up 10% to $36.8 billion in FY2025—driven by high-single-digit volume growth across 18 products hitting record sales, even as legacy assets like Enbrel face biosimilar pressure.
This fresh sell-side perspective arrives amid Amgen's post-Horizon Therapeutics integration, where acquired rare disease drugs like Tepezza and Krystexxa have bolstered the portfolio. With no prior titles on this topic, the initiation underscores why investors should reassess AMGN now: a shift from patent-cliff fears to diversified growth, though valuation limits upside.
Amgen's Business: Biotech Stalwart with Rare Disease Pivot
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology firm focused on human therapeutics across oncology, inflammation, bone health, cardiovascular, and rare diseases. Its portfolio spans blockbusters like Prolia ($4.4B in FY2025 sales, +1% YoY) and emerging stars like Repatha ($3.0B, +36%). The $27.8B Horizon acquisition in October 2023 added first-in-class assets, pushing total product sales to $35.1B in FY2025 (+10% YoY), with U.S. sales at 73% of the mix.
Amgen operates as a single reportable segment, emphasizing marketed products and a pipeline including obesity candidate MariTide. Market position remains strong in a $500B+ global biotech space, though peers like AbbVie (ABBV) grapple with similar immunology transitions.
Financial Trajectory: 10% Growth Amid Product Shifts
Amgen delivered robust top-line expansion in FY2025, with total revenues reaching $36.8B (+10% YoY from $33.4B in FY2024). Product sales drove the gains, up 10% to $35.1B, fueled by 13% volume growth offset by 3% lower net pricing. GAAP EPS surged 88% to $14.23, aided by revenue momentum and equity gains, though non-GAAP EPS rose more modestly 10% to $21.84.
Quarterly trends show acceleration:
| Metric ($M) | Q3'25 | Q3'24 | YoY | Q2'25 | Q2'24 | YoY | FY'25 | FY'24 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 9,557 | 8,503 | +12% | 9,179 | 8,388 | +9% | 36,751 | 33,424 | +10% |
| Product Sales | 9,137 | 8,151 | +12% | 8,771 | 8,041 | +9% | 35,148 | 32,026 | +10% |
| Operating Income | N/A | N/A | N/A | 2,656 | 1,909 | +39% | 9,080 | 7,258 | +25% |
| Diluted EPS | N/A | 5.22 | N/A | 2.65 | 1.38 | +92% | 14.23 | 7.56 | +88% |
Key Product Breakdown (FY2025, $M unless noted):
| Product | FY'25 Sales | YoY | Notes |
|---|---|---|---|
| Prolia | 4,414 | +1% | Steady bone health leader |
| Repatha | 3,016 | +36% | 44% Q4 growth on volume/price |
| Otezla | 2,265 | +6% | Oral psoriasis, $1.2B impairment |
| Enbrel | 2,226 | -33% | Biosimilar erosion accelerates |
| Evenity | 2,100 | +34% | Osteoporosis ramp-up |
| Xgeva | 2,084 | -6% | Oncology support stable |
| Tepezza | 1,903 | +3% | Horizon add-on, thyroid eye disease |
Growth engines like Repatha (Q4'25: $870M, +44%) and Evenity ($599M Q4, +39%) offset Enbrel's -30% Q3 decline to $580M. Horizon contributions (Tepezza, Krystexxa at $1.3B+ combined) added ~10% to sales post-close. Free cash flow dipped to $8.1B from $10.4B due to working capital and capex, supporting $5B+ dividends and buybacks.
Margins faced pressure: GAAP operating margin rose to 25.8% (+310bps), but non-GAAP dipped to 46.1% (-80bps) on higher expenses (+6% to $27.7B), including R&D investments in later-stage programs.
Investment Thesis: Balanced Growth Story with Execution Risks
Bull Case: Amgen's diversification thesis holds—newer products (Repatha, Evenity, Tezspire up 71% to $1.5B) deliver mid-teens growth, offsetting ~10% legacy erosion (Enbrel). Horizon integration yields 20%+ CAGR in rare diseases; pipeline catalysts like MariTide Phase 3 data in 2026 could unlock obesity blockbuster potential. At ~17x FY2026E EPS (implied by $366 PT), AMGN trades below historical 20x average and peers (ABBV ~15x, VRTX ~25x), pricing in conservative 5-7% growth despite 10% FY2025 delivery.
Bear Case: Biosimilar headwinds intensify—Enbrel U.S. exclusivity ended 2023, with sales down 33%; Prolia/Xgeva face 2025-2030 cliffs per 10-K disclosures. IRA price controls hit Medicare (e.g., Otezla selected), squeezing ASPs; OB3/OBBBA reforms add reimbursement risks. R&D spend (+ on MariTide) risks failures, while $40B+ debt from Horizon elevates leverage amid 5% yields.
Canaccord's Hold/$366 aligns with 5% upside from recent levels ($350 assumed), baking in 8-10% EPS growth but capping multiples on policy risks. Market misprices pipeline optionality, but legacy drag caps re-rating.
Catalysts to Watch
- Q4'25 Earnings (Feb 2026): Confirm 10%+ guide; Repatha/Evenity volume trends.
- MariTide Data (2026): Obesity readout could add $5B+ peak sales if superior to GLP-1s.
- Biosimilar Impact: Track Enbrel/Prolia share loss vs. 10-K risks.
Stance: Hold. Steady grower at fair value; monitor IRA execution and pipeline for upgrades.
Sources: AMGN 10-K/Q (FY2025, Q3'25), 8-K earnings releases, SEC filings via semantic search.